Symbiotec Pharmalab Ltd (SYMBIOTEC) — Announcement | 29 September 2026 (2 announcements)

29 September 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

1Announcement🔴 High Importance Neutral📄 PDF

📢 Key Event

Symbiotec receives FDA VAI classification for Pithampur facility

💡 Investor Takeaway

Routine procedural filing with no direct impact on shareholders.

Symbiotec Pharmalab announced it received a U.S. FDA Establishment Inspection Report for its Pithampur manufacturing facility with a Voluntary Action Indicated classification, confirming compliance after an August 2026 inspection. This regulatory milestone supports ongoing export readiness and potential revenue growth from U.S. markets.

2Announcement Neutral📄 PDF

📢 Key Event

Trading window closes for insiders ahead of Q3 results

💡 Investor Takeaway

Routine procedural filing with no direct impact on shareholders.

Symbiotec Pharmalab announced that its trading window closes on October 1, 2026, for insiders until 48 hours after the unaudited Q3 results release, as required by SEBI regulations. This routine compliance measure restricts insider trading during a critical reporting period.

📊 Stock Analysis — SYMBIOTEC ✨ Ask AI About This

About Symbiotec Pharmalab Ltd (SYMBIOTEC)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹6,629.52 Cr

View full SYMBIOTEC stock details →

📡 Get AI alerts when SYMBIOTEC files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SYMBIOTEC — Free

💡 Ask AI about this filing

"When will the VAI status enable new U.S. product launches?""How does this classification affect Symbiotec's export revenue growth?""What is the timeline for full FDA approval of the Pithampur facility?"

Ask AI Free →

📊 More SYMBIOTEC filings

🔴 Announcement — 28 September 2026Symbiotec Pharmalab reported Q1 FY27 revenue of INR218 crores, up 7% YoY, driven by 6% growth in its...
🔴 Announcement — 22 September 2026Symbiotec Pharmalab announced that the audio recording of its Q1 FY2026 earnings conference call is ...
🔴 Financial Results — 21 September 2026Symbiotec Pharmalab reported Q1FY27 revenue of **₹218.2 crores**, up from ₹203.2 crores YoY, driven ...
🔴 Financial Results — 21 September 2026Symbiotec Pharmalab reported consolidated revenue of **₹2,181.50 crores** for Q1 FY2026, up from **₹...
🟡 Board Meeting — 21 September 2026The Board of Directors of Symbiotec Pharmalab approved unaudited standalone and consolidated financi...

See all SYMBIOTEC filings →

🔥 Also filed on 29 September 2026

ADANIPOWERAdani Power LtdAnnouncement APOLLOApollo Micro Systems LtdAnnouncement ADANIENTAdani Enterprises LtdAnnouncement ADANIPORTSAdani Ports & Special Economic Zone LtdAnnouncement PFOCUSPrime Focus LtdAnnouncement MCXMulti Commodity Exchange of India LtdAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SYMBIOTEC files new disclosures

Track SYMBIOTEC filings, board meetings, and corporate actions. Free email alerts at 5 PM.